Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Endocrinology

Biology and the Path to Diagnosis

At a Glance

INSR deficiency is caused by changes in the insulin receptor gene that disrupt insulin signaling, leading to severe insulin resistance, very high insulin levels, and sometimes low blood sugar. Diagnosis combines clinical findings, laboratory tests, and genetic evaluation.

To understand an INSR-related syndrome, it helps to imagine the body’s cells as a high-security building. In a typical person, insulin is the key that opens the door to let sugar (glucose) in. In someone with an INSR mutation, the building’s doors (the insulin receptors) have altered or reduced signaling—they are either broken, missing, or have jammed locks [1][2].

The Biology of Altered Receptor Signaling

The INSR gene provides the instructions for building the insulin receptor. A mutation—a typo in those instructions—can cause the receptor to fail in several distinct ways:

  • Production and Assembly: Some mutations prevent the body from making enough receptors or prevent the “proreceptor” from being cut into its final, working shape [1][3].
  • Delivery Issues: The receptor might be built correctly but fail to reach the surface of the cell, where it is needed to “catch” insulin [4].
  • Binding Defects: The receptor reaches the surface, but the “lock” is the wrong shape. Insulin (the key) cannot grab onto the receptor effectively [2][5].
  • Signaling Failures: Even if insulin “unlocks” the door, the signal to let sugar in never reaches the inside of the cell. This is often caused by a defect in tyrosine kinase activity, which is the internal engine that powers the receptor’s signal [6][7].

Distinguishing the Look-Alikes

Because extreme insulin resistance is rare, it is often confused with more common conditions. Getting the right diagnosis is critical because the treatment for these “look-alikes” can be very different. Diagnosis depends on integrating physical symptoms, laboratory tests (like glucose and C-peptide), lipid profiles, and genetic evaluation.

Condition Primary Cause Key Diagnostic Clues
INSR Deficiency Genetic mutation in the insulin receptor [8]. Extreme insulin levels in lean patients; paradoxical hypoglycemia [8][9].
PCOS Hormonal imbalance, often with mild insulin resistance [10]. Common in the general population; substantial clinical overlap with mild Type A [11].
Lipodystrophy Genetic or acquired loss of body fat [12]. Visible loss of fat; very high triglycerides (blood fats); fatty liver disease [13][14].
Type B Insulin Resistance The immune system attacks the insulin receptor [15]. Typically starts suddenly in adults; often associated with autoimmune diseases like lupus [16][17].

Note: Normal triglycerides and lower insulin levels are helpful clues, but they are not absolute diagnostic cutoffs. Severe INSR disease can have abnormal lipids, and lipodystrophy can overlap phenotypically with severe INSR disease.

The Diagnostic Journey

Doctors typically begin with clinical observations, such as extreme insulin levels (hyperinsulinemia) in someone who is not overweight [8]. Genetic testing is a key part of the evaluation, though a negative test does not automatically rule out all forms of severe insulin resistance (such as Type A).

  • Multigene Panels: These tests look at many genes at once that are known to cause insulin resistance or rare forms of diabetes [18].
  • Exome or Genome Sequencing: If a panel is negative, doctors may use these broader tests to look at all the DNA to find rare or “novel” (newly discovered) mutations [19][20].

Deciphering Your Genetics Report

A genetics report can be difficult to read. It is highly recommended to review it with a clinical geneticist or genetic counselor. Look for these three critical pieces of information:

  1. Variant Classification: Variants are usually ranked from Pathogenic (known to cause disease) to Benign (harmless) [21]. If a report lists a Variant of Uncertain Significance (VUS), it means the mutation is rare, and scientists aren’t yet sure if it causes the disease. A VUS alone should not guide treatment or family planning [22][23].
  2. Zygosity: This tells you how many copies of the mutation you have. Heterozygous means one copy. Biallelic (homozygous or compound heterozygous) means two copies, which strongly supports more severe syndromes like Donohue or Rabson-Mendenhall [21][6].
  3. Functional Testing: If a mutation is a VUS, specialists may perform lab tests to see if the receptor fails to bind insulin or signal correctly [3][7]. While helpful, these tests do not automatically “upgrade” a VUS to a Pathogenic classification [22].

Testing biological parents can help determine if a mutation was inherited or happened for the first time in the patient (de novo) [24][23]. This information is vital for understanding how the condition might affect other family members [25][26].

Common questions in this guide

How do INSR mutations cause hyperinsulinism and insulin resistance?
The INSR gene makes the insulin receptor, which helps cells respond to insulin and take in glucose. A mutation can reduce receptor production, keep it from reaching the cell surface, prevent insulin binding, or disrupt internal signaling. The result can be severe insulin resistance with very high insulin levels and, in some cases, paradoxically low blood sugar.
What tests are used to diagnose INSR deficiency?
Doctors consider physical findings and patterns of insulin, glucose, C-peptide, and lipid results, then use genetic testing to look for INSR variants. A multigene panel is often used first, with exome or genome sequencing considered if the panel is negative. The evaluation also helps distinguish INSR deficiency from PCOS, lipodystrophy, and type B insulin resistance.
What is the difference between a heterozygous and biallelic INSR result?
Heterozygous means a variant is present in one copy of the INSR gene, while biallelic means variants affect both copies, either as matching or different variants. Biallelic changes strongly support more severe conditions such as Donohue syndrome or Rabson-Mendenhall syndrome, but the result must be interpreted with clinical findings and other testing.
What does a VUS mean on an INSR genetic test?
A Variant of Uncertain Significance, or VUS, is a rare genetic change whose effect is not yet known. A VUS by itself does not confirm INSR deficiency and should not be used alone to choose treatment or make family-planning decisions. A clinical geneticist or genetic counselor may review family testing and functional studies, although these studies do not automatically change the classification.
Can INSR deficiency still be possible if a genetic panel is negative?
Yes. A negative multigene panel does not rule out every cause of severe insulin resistance, including some forms of Type A insulin resistance. Doctors may consider exome or genome sequencing to search more broadly for rare or newly recognized variants, while also using clinical and laboratory findings.
Why might my parents need genetic testing for an INSR variant?
Testing biological parents can show whether an INSR variant was inherited or arose de novo, meaning it appeared for the first time in the patient. This information can help clarify the diagnosis and estimate whether other family members may be affected or need evaluation. A genetic counselor can explain what the results mean for family planning.

Get notified when new evidence is published on Hyperinsulinism due to INSR deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (26)
  1. 1

    Structural Basis and Genotype-Phenotype Correlations of INSR Mutations Causing Severe Insulin Resistance.

    Hosoe J, Kadowaki H, Miya F, et al.

    Diabetes 2017; (66(10)):2713-2723 doi:10.2337/db17-0301.

    PMID: 28765322
  2. 2

    Molecular mechanisms of insulin resistance in 2 cases of primary insulin receptor defect-associated diseases.

    Tsuji-Hosokawa A, Takasawa K, Nomura R, et al.

    Pediatric diabetes 2017; (18(8)):917-924 doi:10.1111/pedi.12508.

    PMID: 28181734
  3. 3

    Clinical and Functional Characterization of Novel INSR Variants in Two Families With Severe Insulin Resistance Syndrome.

    Zhou Q, Yu J, Yuan X, et al.

    Frontiers in endocrinology 2021; (12()):606964 doi:10.3389/fendo.2021.606964.

    PMID: 33995269
  4. 4

    An INSR-BECN1-KIAA0825 complex prevents hepatocytic insulin receptor secretion via extracellular vesicles against monogenic diabetes.

    Kuramoto K, Chen M, He C

    bioRxiv : the preprint server for biology 2026; doi:10.64898/2026.09.13.751259.

    PMID: 42779891
  5. 5

    Deep mutational scanning of the human insulin receptor ectodomain to inform precision therapy for insulin resistance.

    Aslanzadeh V, Brierley GV, Kumar R, et al.

    Nature communications 2025; (16(1)):9143 doi:10.1038/s41467-025-64178-4.

    PMID: 41093840
  6. 6

    Comprehensive assessment of the genotype-phenotype spectrum and treatment for monoallelic insulin receptoropathy in a cohort of 505 people.

    Brown RJ, Xu J, Luan J, et al.

    Research square 2026; doi:10.21203/rs.3.rs-10884175/v1.

    PMID: 42856426
  7. 7

    Severe insulin resistance in disguise: A familial case of reactive hypoglycemia associated with a novel heterozygous INSR mutation.

    Innaurato S, Brierley GV, Grasso V, et al.

    Pediatric diabetes 2018; (19(4)):670-674 doi:10.1111/pedi.12632.

    PMID: 29411486
  8. 8

    Hyperinsulinemic hypoglycemia due to pathogenic INSR variants: metabolic signature, phenotypic overlap, and semidominant inheritance.

    Marcelino do Nascimento R, Dos Santos A, Guadagnini D, et al.

    Frontiers in endocrinology 2026; (17()):1716020 doi:10.3389/fendo.2026.1716020.

    PMID: 42181197
  9. 9

    Pre-gestational diabetes in a young woman with a pathogenic INSR missense mutation, p.(Met1180Lys).

    Prehn EL, Crowley M, Fennell D, et al.

    Endocrinology, diabetes & metabolism case reports 2025; (2025(1)).

    PMID: 39922186
  10. 10

    Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.

    Gambineri A, Zanotti L

    Nucleus (Austin, Tex.) 2018; (9(1)):392-397 doi:10.1080/19491034.2018.1509659.

    PMID: 30131000
  11. 11

    Type A insulin resistance syndrome misdiagnosed as polycystic ovary syndrome: a case report.

    Lin L, Chen C, Fang T, et al.

    Journal of medical case reports 2019; (13(1)):347 doi:10.1186/s13256-019-2304-4.

    PMID: 31771632
  12. 12

    Primary disease of adipose tissue: When to think about and how to evaluate it in clinical practice?

    Vatier C, Vigouroux C, Mosbah H

    Annales d'endocrinologie 2024; (85(3)):190-194 doi:10.1016/j.ando.2024.05.019.

    PMID: 38871502
  13. 13

    Familial Partial Lipodystrophy (FPLD): Recent Insights.

    Bagias C, Xiarchou A, Bargiota A, Tigas S

    Diabetes, metabolic syndrome and obesity : targets and therapy 2020; (13()):1531-1544 doi:10.2147/DMSO.S206053.

    PMID: 32440182
  14. 14

    Lipodystrophy for the Diabetologist-What to Look For.

    Patni N, Garg A

    Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.

    PMID: 35821558
  15. 15

    Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China.

    Zhao L, Li W, Liu L, et al.

    The Journal of clinical endocrinology and metabolism 2023; (109(1)):e175-e181 doi:10.1210/clinem/dgad461.

    PMID: 37536271
  16. 16

    Type B insulin resistance syndrome associated with connective tissue disease and psoriasis.

    Łebkowska A, Krentowska A, Adamska A, et al.

    Endocrinology, diabetes & metabolism case reports 2020; (2020()).

    PMID: 32755965
  17. 17

    Type B insulin resistance with glycemic extremes: a case report and literature review.

    Ngo EMT, Rowe JM, Chillon TS, et al.

    Frontiers in endocrinology 2026; (17()):1852784 doi:10.3389/fendo.2026.1852784.

    PMID: 42255432
  18. 18

    Hereditary severe insulin resistance syndrome: Pathogenesis, pathophysiology, and clinical management.

    Iqbal J, Jiang HL, Wu HX, et al.

    Genes & diseases 2023; (10(5)):1846-1856 doi:10.1016/j.gendis.2022.03.016.

    PMID: 37492723
  19. 19

    Massively Parallel Sequencing for Rare Genetic Disorders: Potential and Pitfalls.

    McInerney-Leo AM, Duncan EL

    Frontiers in endocrinology 2020; (11()):628946 doi:10.3389/fendo.2020.628946.

    PMID: 33679611
  20. 20

    Monogenic diabetes: An evidence-based clinical approach.

    Bhattacharya S, Fernandez CJ, Kamrul-Hasan ABM, Pappachan JM

    World journal of diabetes 2025; (16(5)):104787 doi:10.4239/wjd.v16.i5.104787.

    PMID: 40487603
  21. 21

    Insulin receptor variants: Extending the traditional Mendelian spectrum.

    Collin-Chavagnac D, Saint-Martin C, Bedidi L, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2025; (27(6)):101404 doi:10.1016/j.gim.2025.101404.

    PMID: 40094207
  22. 22

    A de novo INSR variant in Type A insulin resistance syndrome: familial investigation and genetic implications.

    Lin X, Xu ZY, Xie LJ, et al.

    Gene 2026; (979()):149934 doi:10.1016/j.gene.2025.149934.

    PMID: 41360184
  23. 23

    A Case Report: Treatment, follow-up, and literature review of type A insulin resistance syndrome caused by a De Novo INSR c.3328G>C mutation.

    Ji C, Zheng X, Wang Q, Chen Z

    Frontiers in endocrinology 2026; (17()):1840942 doi:10.3389/fendo.2026.1840942.

    PMID: 42272804
  24. 24

    Novel heterozygous mutations of the INSR gene in a familial case of Donohue syndrome.

    Qin L, Li X, Hou Q, et al.

    Clinica chimica acta; international journal of clinical chemistry 2017; (473()):26-31 doi:10.1016/j.cca.2017.08.007.

    PMID: 28803747
  25. 25

    From genotype to phenotype: reverse phenotyping of a novel INSR variant in a large family with hyperinsulinemic hypoglycemia.

    Soltanova L, Erbilgin Y, Menkli Y, et al.

    Journal of applied genetics 2026; doi:10.1007/s13353-026-01121-3.

    PMID: 42891915
  26. 26

    Family with two novel in cis INSR gene variants: Phenotypic evolution with age.

    Sotiriou G, Mertzanian A, Raptopoulou ME, et al.

    Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2026; (35(4)):351-356 doi:10.1297/cpe.2026-0014.

    PMID: 42825299

This page is for informational purposes only and does not constitute medical advice about INSR-related hyperinsulinism. An endocrinologist or genetic counselor should interpret your or your child's genetic and laboratory results.

Guide contents Hyperinsulinism due to INSR deficiency
Research & Literature
02 Warning Signs and Emergency Presentations 04 The INSR Severity Spectrum